These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16625817)

  • 1. Obesity drugs in clinical development.
    Halford JC
    Curr Opin Investig Drugs; 2006 Apr; 7(4):312-8. PubMed ID: 16625817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity treatment: novel peripheral targets.
    Field BC; Chaudhri OB; Bloom SR
    Br J Clin Pharmacol; 2009 Dec; 68(6):830-43. PubMed ID: 20002077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.
    Rubinić I; Kurtov M; Likić R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1243. PubMed ID: 39016695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug strategies for the treatment of obesity.
    Alemany M; Remesar X; Fernández-López JA
    IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
    Zieba R
    Postepy Hig Med Dosw (Online); 2007 Oct; 61():612-26. PubMed ID: 17971763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging drug molecules against obesity.
    George M; Rajaram M; Shanmugam E
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy for obesity.
    Neff LM; Aronne LJ
    Curr Atheroscler Rep; 2007 Dec; 9(6):454-62. PubMed ID: 18377785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of appetite suppression: implication for the treatment of obesity.
    Halford JC
    Curr Drug Targets; 2001 Dec; 2(4):353-70. PubMed ID: 11732637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational studies on PYY as a novel target in obesity.
    Zac-Varghese S; De Silva A; Bloom SR
    Curr Opin Pharmacol; 2011 Dec; 11(6):582-5. PubMed ID: 22019565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.
    Roth JD; Coffey T; Jodka CM; Maier H; Athanacio JR; Mack CM; Weyer C; Parkes DG
    Endocrinology; 2007 Dec; 148(12):6054-61. PubMed ID: 17761760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
    Srivastava G; Apovian C
    Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-obesity drugs.
    Proietto J
    Med J Aust; 1998 Apr; 168(8):409-12. PubMed ID: 9594954
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-obesity drugs: status quo and recent advances.
    Zhu HJ; Jin ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Jun; 33(3):243-7. PubMed ID: 21718603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut hormones: implications for the treatment of obesity.
    Neary MT; Batterham RL
    Pharmacol Ther; 2009 Oct; 124(1):44-56. PubMed ID: 19560488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment of obesity.
    Bray GA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined oleoyl-estrone and rimonabant on overweight rats.
    Ferrer-Lorente R; Cabot C; Fernández-López JA; Alemany M
    J Pharmacol Sci; 2007 Jun; 104(2):176-82. PubMed ID: 17558182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.